We work closely with entrepreneurs and investors at the forefront of the global healthcare revolution. Our in-depth sector knowledge, combined with our technical capability, enables us to help corporates and investors capitalise on the enormous opportunities across the sector as they seek to consolidate and grow their market positions.
The ageing population, technological change, and increased demand for healthcare products and services, all create great opportunities in the health and social care, medical devices, life sciences, bioscience and pharmaceutical markets. Our job is to help our clients maximise those opportunities.
Adviser to Gradiente on raising finance to support the acquisition of a majority stake in the share capital of Giuriati Group S.r.l.
View moreAdviser to Veranex and Summit Partners on the acquisition of IMMR
View moreAdviser to Alflow Scandinavia A/S on the sale to Indutrade AB
View moreAdviser to Banook and Turenne Capital on the acquisition of Nabios
View moreAdviser to Groupe Saint-Gatien on the sale of Théraé Centre Médical to Colisée
Adviser to Meet Recruitment on its MBO supported by NorthEdge Capital
View moreAdviser to Dominique Dutscher on the acquisition of AH Diagnostics
View moreAdviser to Laboratorios Ordesa on the acquisition of Laboratorios Sodeinn, S.L.
View moreAdviser to shareholding management on the sale of a majority stake in Aegide Domitys to AG2R La Mondiale
Advisor to SRS on its reinvestment in DomusVi alongside ICG and Management
View moreAdviser to Palatine Private Equity on its investment in Routes Healthcare
View moreAdviser to PRIMA on its majority sale to Lideta
View moreLuc Bertholat, Partner, Naxicap PartnersClearwater has been very professional in leading the process involving candidates from all over the world.
The team were quickly able to identify the right partner for us and used their excellent relationship with the buyer to help negotiate a transaction that met our objectives.Dan Smart, CEO, Proclinical
With in-depth knowledge and technical capability, our healthcare team has a great track record of delivering tailored solutions.
See our teamOver 65
deals advised upon
in the last 5 years
€9.4bn
deal value
over the last 5 years
Over 40%
deals involving PE
in the last 5 years
Following the publication of the Q2 2021 Clearwater International Multiples Heatmap, Unquote interviewed Clearwater’s executive team to discuss valuation trends in European private equity.
Read more
While dealflow slowed in the UK and Ireland in Q2, the region remains incredibly busy – and a rich pool of attractive assets in the technology, financial and healthcare sectors has pushed average entry multiples to new heights.
Read more
After a record-breaking first quarter, the pace of European PE dealmaking eased in Q2 2021 – although activity remained at near-historic highs.
Read more
